GW Pharma Soars On Strong Epidiolex Sales
Childhood Epilepsy Drug In Demand In US
With its lead cannabinoid product Epidiolex continuing to advance, the London-headquartered, NASDAQ-listed firm has begun late-stage trials in the US with nabiximols, which looks likely to become its second approved drug.
